FDA Approved Hepcludex, Closing the US Gap in Hepatitis D Treatment
Read moreUnitedHealth's Q1 2026 Cost Ratio Eased to 83.9 Percent
Read more
Melatonin for Sleep: What the Evidence Supports and What Gummies Overshoot
Melatonin helps with circadian timing problems, not general insomnia — and analyses keep finding gummies with far more hormone than the label claims.
Supplements
Do Multivitamins Work? What the USPSTF and Large Cohorts Concluded
For preventing heart disease, cancer or death in healthy adults, the evidence favors food — with narrower benefits in specific groups.
Supplements
How to Read a Supplement Facts Label Like a Pharmacist
Serving sizes, %DV, proprietary blends and the asterisk: six lines on the panel that tell you what you are really buying.
Supplements
Supplement-Drug Interactions: The Pairings That Send People to the Hospital
St. John's wort, grapefruit-like effects, and vitamin K flip-flops: documented interactions between common supplements and common prescriptions.
Supplements
USP, NSF and Informed Sport: What Supplement Certification Seals Actually Verify
Third-party seals do not certify that a supplement works — they certify what is in the bottle, how much, and what is not.
Insurance
See all →
Deductibles Explained: Why You Pay Before Insurance Kicks In
The deductible is the number that decides how much of a bad year you pay for yourself.
Underwriting After the ACA: What Health Insurers Can and Cannot Price On
Guaranteed issue ended medical rejection for ACA-compliant plans, but rating still moves on age, geography, tobacco and plan type — and outside the ACA, old rules persist.
Medicaid Expansion: Who Qualifies at 138 Percent of the Poverty Line — and Who Falls in the Gap
Forty states and the District of Columbia have expanded Medicaid to most adults under 138 percent of poverty; in the remaining holdout states, adults too poor for subsidies still have no option.
Research
Surrogate Endpoints: When a Trial Measures a Stand-In Instead of the Outcome You Care About
Trials often track cholesterol, tumor shrinkage or blood sugar instead of death, fractures or survival — the stand-in usually works, but history records the exceptions.
“50% Higher Risk”: Relative vs Absolute Risk in Health News
Relative risk makes small dangers look enormous and big benefits look magical; converting to absolute numbers takes one minute and changes every conclusion.
FDA Approval vs 510(k) Clearance: Two Words That Sound Alike and Mean Different Things
A cleared device reached the market by demonstrating similarity to a decades-old predicate; an approved drug faced clinical trials — knowing which word your product carries changes its evidentiary weight.
Coverage
UnitedHealth Raised Its 2026 Forecast as Cost Ratio Cooled to 86.7 Percent
The July 16, 2026 quarter showed the 2025 cost surge has crested, with guidance lifted to $19.50-$20.00 adjusted EPS. What margin recovery means for members.
AHIP and Blue Cross Blue Shield Pledged New Prior Authorization Reforms
Late-June 2026 commitments from the two biggest insurer trade groups target shrinking prior auth lists and honoring approvals across plan switches.
MedPAC's June Report Lands With Medicare Advantage at 55 Percent
The June 15, 2026 report to Congress arrived as MA enrollment passed 55 percent of beneficiaries and oversight findings piled up. What its recommendations could change.
Health News
FDA Approved Orzeyful, Replacing What Narcolepsy Type 1 Patients Lack
The August 5, 2026 approval of oveporexton brings the first orexin receptor agonist to market — wakefulness restored, not stimulated. What patients should ask.
FDA Approved Lipfendra, the First Oral PCSK9 Inhibitor, for High LDL
The July 15, 2026 approval of enlicitide turns an injection class costing thousands per year into a daily pill. Trial numbers, coverage questions, what's next.
FDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs
The June 17, 2026 approval of tebipenem lets some kidney-infection patients leave the infusion chair for a pill — if stewardship rules hold the line on use.
Latest
How to Read an EOB: What Each Line of Your Explanation of Benefits Means
The explanation of benefits is not a bill — it is the insurer's account of what happened to a claim, and three of its fields decide whether you pay the right amount.
FDA Approved Hepcludex, Closing the US Gap in Hepatitis D Treatment
The May 22, 2026 approval of bulevirtide brings the entry-blocker used in Europe since 2020 to US adults with chronic hepatitis delta. Who should be tested.
UnitedHealth's Q1 2026 Cost Ratio Eased to 83.9 Percent
The April 21, 2026 report showed $111.7 billion in revenue and the first cost-ratio relief after 2025's claims surge. Why that cuts both ways for consumers.
How to Read a Meta-Analysis: What Pooling Studies Can and Cannot Fix
Meta-analyses sit at the top of the evidence pyramid, but pooling inherits every flaw of the studies it combines — heterogeneity, publication bias and garbage in.